Oramed Pharmaceuticals (ORMP) Cash from Investing Activities (2010 - 2026)

Oramed Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at -$19.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 182.52% year-over-year to -$19.5 million; the trailing twelve-month figure through Mar 2026 stood at -$37.7 million (down 137.87% YoY), and the FY2025 full-year result was $5.4 million, down 94.86% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$19.5 million, down from -$1.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $94.7 million in Q2 2024, with the low at -$75.1 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $2.9 million across 5 years, with a median of $7.4 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 6212.45% — and 2024, when it soared 743.47%.
• Oramed Pharmaceuticals' Cash from Investing Activities stood at $11.3 million in 2022, then soared by 166.4% to $30.0 million in 2023, then sank by 48.58% to $15.4 million in 2024, then tumbled by 110.92% to -$1.7 million in 2025, then sank by 1057.24% to -$19.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$19.5 million (Q1 2026), -$1.7 million (Q4 2025), and $38.4 million (Q3 2025), per Business Quant data.